Alexion Pharmaceuticals is set to acquire Swedish biopharma Wilson Therapeutics via a wholly-owned subsidiary for $855 million.
The transaction grants Alexion access to Wilson Therapeutics’ product, WTX101, which is currently in Phase 3 development as a treatment for Wilson disease – a rare genetic disorder with devastating hepatic and neurological consequences for patients.
WTX101 is a first-in-class oral copper-binding agent with a unique mechanism of action and ability to access and bind copper from serum and promote its removal from the liver.
The treatment has received Fast Track designation in the U.S. and Orphan Drug Designation for the treatment of Wilson disease in the US and EU.
Wilson disease is a rare disorder that can lead to severe liver disease, including cirrhosis and acute liver failure, as well as debilitating neurological morbidities such as impaired movement, gait, speech, swallowing, and psychiatric disorders.
“WTX101 is an innovative product that addresses the underlying cause of the disease and has the potential to define a new standard of care in treating Wilson disease, an area that has not had a new treatment in over two decades,” said Alexion CEO Ludwig Hantson.
“The acquisition of Wilson Therapeutics is a strong strategic fit for Alexion given the overlap with our current clinical and commercial focus on metabolic and neurologic disorders, and is an important first step in rebuilding our clinical pipeline.”